Nasdaq
$7.62▼ 0.35%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.94BShares out 2.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 9.2After-hours26.09.03 05:164Ownership#●●●#●●●
BIOCRYST PHARMACEUTICALS INC
Jon P. Stonehouse, an executive at BioCryst Pharmaceuticals, reported a change in beneficial ownership of company securities via SEC Form 4 on August 31, 2026. This filing formalizes the update to the insider's stock holdings.…more
$7.62-0.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.2After-hours26.09.03 05:134Ownership
BIOCRYST PHARMACEUTICALS INC
BioCryst Pharmaceuticals insider Jill C. Milne filed a Form 4 on September 2, 2026, reporting changes in beneficial ownership of securities as of August 31, 2026. This filing serves as a standard regulatory disclosure of insider equity transactions and does not indicate a material change in corporate governance or financial status.…more
$7.62-0.35%vs prev closeView filingShare - 9.2After-hours26.09.03 05:104Ownership
BIOCRYST PHARMACEUTICALS INC
Insider Vincent Milano of BioCryst Pharmaceuticals reported a change in beneficial ownership of securities as of August 31, 2026. This filing serves as an official notification to the SEC regarding the insider's equity position change.…more
$7.62-0.35%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoAfter-hours26.10.22 05:01#●●●#●●●
BioCryst to Report Third Quarter 2026 Financial Results on November 4
BioCryst Pharmaceuticals will release its financial results for the third quarter of 2026 on November 4. The company will host a conference call and webcast to discuss the results and provide a corporate update.…more
$7.62-0.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 4d agoPre-market26.10.21 20:00
●●●●●●●● ●●●●● ●●●●●●
BioCryst Pharmaceuticals announced that the U.S. FDA approved its 150 mg oral pellet formulation of ORLADEYO for the prophylaxis of HAE in adults and adolescents. This new formulation provides an alternative administration option for patients who have difficulty swallowing capsules, potentially expanding the drug's market reach.…more
$7.62-0.35%vs prev close - 10.5Pre-market26.10.05 20:00
●●●●●●●● ●●●●● ●●●●●●
BioCryst Pharmaceuticals has established a seven-member Scientific Advisory Board to provide strategic guidance for its research and development initiatives. This move is part of the company's broader strategy to enhance its rare disease pipeline through external innovation.…more
$7.62-0.35%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report